(MENAFN - ProactiveInvestors) Regeneus (ASX: RGS) has achieved a key milestone with the manufacture of its off-the-shelf stem cell therapy product Progenza for its First-in-Human trial for the treatment of osteoarthritis. The company is on track to receive ethics approval and commence recruitment for the trial in the first-half of 2015. Adding interest the company highlighted the benefit of using adipose or fat tissue over other tissue types by demonstrating the capacity to produce millions of therapeutic doses of Progenza from a single donor. The production of commercial quantities of stem cells from a single donor is critical to maximise dose-to-dose consistency chief executive officer John Martin said. This scale of production will minimise clinical trial and regulatory risks while reducing the cost of the final product. One of the key advantages for manufacturing Progenza at industrial scale is that it uses stem cells sourced from adipose or fat tissue. Adipose tissue is readily available from donors in large quantities and has significantly higher stem cells per gram of tissue than other tissue sources such as bone marrow or cord tissue. Also adipose derived stem cells show greater capacity for expansion than stem cells from other tissue types. Progenza adipose … Continue reading →

London, UK (PRWEB) April 09, 2015 Pharmacos are developing more effective drug delivery vehicles with the aid of nanotechnology. Lack of specificity induces undue drug wastage, reduced potency and undesirable side effects during treatment. This is a serious problem, especially when a patient is suffering from cancer, where the use of chemotherapy is part of therapeutic regimen. Easy modification, customisability and product cost are set to be the major factors determining the commercial success apart from their pharmacological benefits. Heavy investments in R&D are poised to assist in identifying effective nanoparticle-based drug delivery vehicles. Manifold nanotechnology-based devices, medicines, chips and sensors are undergoing various stages of clinical trials. To date, there are 144 nanomedicines in clinical development. The majority of the nanomedicines are in pre-clinical development phase, followed by research phase. Only a limited number of products are in the market for few indications; currently, 13 nanomedicines are commercially available in the market. Their clinical pipeline is getting stronger year by year and novel incentives are being taken by pharmacos, but the rate of commercialisation of such products is slow and the market size is still limited. To surmount these barriers, the pace of R&D alongside market introduction needs to … Continue reading →

When Little Brother came up lame six years ago at the age of 8, Brenda Simmons took her horse from one veterinarian specialist to another to find a fix. Injections of the horse's stem cells into a lower leg joint and tendons relieved his pain and returned full function to a horse that had been unridable. "He was better than ever, and he's still going strong," the 58-year-old Granby resident said. "I asked the vet, 'Can you do that for me?' " She couldn't, but a physician in Edwards, Dr. Scott Brandt, did treat her with stem cells. After crippling pain had sidelined her for years, she said, injection of her own stem cells and other living cell products, taken from her bone marrow and fat tissue, has restored the former runner and skier to a more active life over the past year. She had already had one knee-replacement surgery, but she now believes she can avoid a second one. ( | ) "It's not mainstream. It's still in development," Brandt said of treatment that can cost $8,000 to $12,000 and isn't covered by insurance. "But it will happen in our lifetimes. This will delay or prevent many surgeries." Many … Continue reading →